Patent SG-11201903013S-A (SG)
Title: Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
Inventor: NEUMANN CHRISTOPHER SCOTT
IPC: A61K47/68
Filed: 2017-10-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 MEM 0 11101 HOE 100011101 Ell 1101 100 IRMO 11110 1111 011 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/075600 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: CASTELLINO, Angelo et al.; Seattle Genetics, A61K 47/68 (2017.01) INC., 21823 30TH Drive SE, Bothell, Washington 98021 International Application Number: (US). PCT/US2017/057116 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 18 October 2017 (18.10.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/409,765 18 October 2016 (18.10.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, Applicant: SEATTLE GENETICS, INC. [US/US]; TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 21823 30th Drive SE, Bothell, Washington 98021 (US). (84) Designated States (unless otherwise indicated, for every Inventors: NEUMANN, Christopher Scott; 21823 30th kind of regional protection available): ARIPO (BW, GH, Drive SE, Bothell, Washington 98021 (US). OLIVAS, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Kathleen; 21823 30th Drive SE, Bothell, Washington UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 98021 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Unit the (54) © diseases Title: TARGETED DELIVERY 1200 --- 1000 ., 1 E 900 til 800 2 C 700 ce 0 sap 1.- 400 z 300 - w 2 200 100 1100 • > 600 OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS L540cy xenograft model + —a i - II ........... •---, 0 „.... 1111 -le-untreated --a-Ag2.21{8) 10 mgikg -m-Ag2.21{8) 3 m99 -4.-A9.2-21{3} 1 mgtkg -s-h00-21(8) 10 en Ay Ligand Unit through action. Methods for treating and compositions — 0 5 10 15 20 25 30 35 40 45 50 55 60 65 DAYS POST TUMOR IMPLANT Figure I : Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds invention are also disclosed. 11 © © ir) IN 0 .-- - GC (57) - a ei of C [Continued on next page] WO 2018/075600 Al MIDEDIMOMOIDEIREIDIONOMMONIHMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))